Overcoming therapeutic resistance in cutaneous dermatophytosis using ablative fractional laser-assisted delivery of topical antifungals Authors: Elham Behrangi, Roya Zeinali, Abbas Dehghani, Azadeh Goodarzi Published: 2026 ABSTRACT Dermatophytosis, a contagious fungal infection affecting the skin and nails, is increasingly associated with resistance to oral antifungal medications. Laser-assisted drug delivery is a modern therapeutic approach that has shown promising results in various dermatologic conditions, including onychomycosis. This study aims to evaluate the effectiveness of laser-assisted drug delivery in treating refractory cutaneous dermatophyte infections. This case series included five patients with confirmed refractory cutaneous dermatophytosis, unresponsive to oral antifungal treatment for at least six months. Patients were treated at the dermatology clinic of a medical center hospital between June 2024 and March 2025 with three monthly sessions of ablative fractional laser therapy combined with topical application of clotrimazole and terbinafine creams. Clinical outcomes were assessed using a dermatologist-evaluated improvement score based on standardized photographs: worsened (-1), no change (0), slight improvement (1), moderate improvement (2), and significant improvement (3). Patient satisfaction with the treatment was recorded, along with treatment tolerability and any adverse effects. A total of five patients (mean age [range], 46.2 [39–57] years; male-to-female ratio, 2:3) were enrolled. All patients had previously been treated with various oral antifungal therapies, including fluconazole, terbinafine, itraconazole, and voriconazole, without achieving a clinical response after at least six months of treatment. LADD sessions ranged from 1 to 3, and the follow-up period was 1 to 6 months. The highest clinical response (3) was observed in all five patients, with dramatic improvement in pruritus and high patient satisfaction. The evaluation score was 3 in all patients, indicating significant improvement. The procedure was well tolerated, and no serious side effects were reported. The findings of this case series suggest that laser-assisted drug delivery may be a suitable and effective treatment option for dermatophyte infections that are resistant to oral antifungal therapy. Introduction Resistance to oral antifungal therapy in the treatment of skin fungal infections, particularly dermatophytosis, is becoming a significant global concern [1]. These contagious infections affect approximately 20–25% of the global population and, while initially managed with topical antifungal agents, more extensive or treatment-resistant cases often necessitate systemic therapy []. Oral antifungals such as terbinafine and itraconazole have traditionally been effective, but an increasing number of patients are returning with recurrent or refractory infections that do not respond to standard treatments [3, 4]. The growing concern over antifungal resistance and the side effects associated with systemic medications has intensified the search for alternative therapeutic modalities. Laser-assisted drug delivery (LADD) utilizes fractional lasers—such as CO₂ and erbium: YAG—to create microchannels in the skin, thereby enhancing the penetration of topically applied agents in addition to benefit from laser effects [5, 6]. LADD has shown promising results in various dermatological conditions, including photodamaged skin, scars, psoriasis, pigmentary disorders, and more recently, onychomycosis [7, 8]. However, the role of LADD in the treatment of cutaneous dermatophytosis remains underexplored. To our knowledge, no studies have yet evaluated its efficacy specifically in skin fungal infections. This study aims to investigate the therapeutic potential of laser-assisted drug delivery in managing refractory dermatophyte infections of the skin. Method This retrospective case series was conducted at Hazrat Fatemeh Dermatology Clinic between June 2024 and March 2025 following approval from the institutional ethics board. Written informed consent was obtained from all participants. All enrolled patients had a confirmed diagnosis of dermatophyte infection (tinea cruris or tinea corporis) based on clinical evaluation by a dermatologist and confirmed through potassium hydroxide (KOH) preparation and fungal culture. Each patient had previously undergone at least six months of systemic antifungal therapy—including itraconazole, terbinafine, fluconazole, or voriconazole—without achieving satisfactory clinical improvement. Laser-assisted drug delivery was performed using either an ablative fractional CO₂ 10,600 nm laser (SmartXide², DEKA, Italy) or an Er: YAG 2940 nm laser (SP Dynamis, Fotona, USA). Prior to the procedure, topical anesthesia was applied. Each patient was expected to complete three monthly laser treatment sessions. The laser application protocol is demonstrated in Table 1 for each patient. Following each session, the treated lesions were covered with a combination of topical clotrimazole and terbinafine creams, and patients were instructed to keep the area covered and avoid washing for 48 h and continue application twice daily at least for five days. Table 1Patient Demographic, Clinical, and Treatment InformationPatientAge/SexClinical PresentationPrior treatments/DurationTreatment ModalityNumber of SessionsAdditional TreatmentsFollow-upDermatologist Assessment EvaluationPatient Satisfaction1(Fig. 1)44/maleProgressive tinea cruris extending to lower abdomen and thighs from 18 months agotopical antifungalFluconazoleItraconazoleTerbinafineVoriconazole/ 12 monthsFractional CO2 laser with energy 14, stack 1, dwell time 100 and space 4003Continue application of combination of topical terbinafine and clotrimazole creams twice a day for five days following treatment6 mo3Excellent2(Fig. 2)40/FemaleExtensive tinea corporis on legs and hands from 12 months agotopical antifungalFluconazoleItraconazoleTerbinafine/ 10 monthsAblative fractional Er: Yag laser with rejuvenation mode (PSO3) with spot size 7 mm, energy 2 J, 15 Hz3Combination of topical terbinafine and clotrimazole creams twice a day/Weekly oral fluconazole 1505 mo3Excellent3(Fig. 3)39/FemaleTinea corporis on legs and hands from 12 months ago with severe pruritustopical antifungalFluconazoleItraconazoleTerbinafineCombination of Itraconazole and terbinafine/ 11 monthsAblative fractional Er: Yag laser with rejuvenation mode (PSO3) with spot size 7 mm, energy 2 J, 15 Hz2Combination of topical terbinafine and clotrimazole creams twice a day/Weekly oral fluconazole 1506 mo3Excellent(The patient mentioned the dramatic relieve of pruritus)4(Fig. 4)51/MaleRefractory tinea cruris from 10 months ago with severe pruritustopical antifungalItraconazoleTerbinafineVoriconazole/ 8 monthsAblative fractional Er: Yag laser with rejuvenation mode with spot size 7 mm, energy 2 J, 15 Hz2Combination of topical terbinafine and clotrimazole creams twice a day3 mo3Excellent5(Fig. 5)57/FemaleRefractory tinea cruris from 8 months ago with severe pruritus and sleep disturbance from 14 months agotopical antifungalFluconazoleItraconazoleTerbinafineVoriconazole/ 12 monthsAblative fractional Er: Yag laser with rejuvenation mode (PSO3) with spot size 7 mm, energy 2 J, 15 Hz1Combination of topical terbinafine and clotrimazole creams twice a day1 mo3Excellent(The patient mentioned the dramatic relieve of pruritus and sleeping well) Table 1Patient Demographic, Clinical, and Treatment InformationPatientAge/SexClinical PresentationPrior treatments/DurationTreatment ModalityNumber of SessionsAdditional TreatmentsFollow-upDermatologist Assessment EvaluationPatient Satisfaction1(Fig. 1)44/maleProgressive tinea cruris extending to lower abdomen and thighs from 18 months agotopical antifungalFluconazoleItraconazoleTerbinafineVoriconazole/ 12 monthsFractional CO2 laser with energy 14, stack 1, dwell time 100 and space 4003Continue application of combination of topical terbinafine and clotrimazole creams twice a day for five days following treatment6 mo3Excellent2(Fig. 2)40/FemaleExtensive tinea corporis on legs and hands from 12 months agotopical antifungalFluconazoleItraconazoleTerbinafine/ 10 monthsAblative fractional Er: Yag laser with rejuvenation mode (PSO3) with spot size 7 mm, energy 2 J, 15 Hz3Combination of topical terbinafine and clotrimazole creams twice a day/Weekly oral fluconazole 1505 mo3Excellent3(Fig. 3)39/FemaleTinea corporis on legs and hands from 12 months ago with severe pruritustopical antifungalFluconazoleItraconazoleTerbinafineCombination of Itraconazole and terbinafine/ 11 monthsAblative fractional Er: Yag laser with rejuvenation mode (PSO3) with spot size 7 mm, energy 2 J, 15 Hz2Combination of topical terbinafine and clotrimazole creams twice a day/Weekly oral fluconazole 1506 mo3Excellent(The patient mentioned the dramatic relieve of pruritus)4(Fig. 4)51/MaleRefractory tinea cruris from 10 months ago with severe pruritustopical antifungalItraconazoleTerbinafineVoriconazole/ 8 monthsAblative fractional Er: Yag laser with rejuvenation mode with spot size 7 mm, energy 2 J, 15 Hz2Combination of topical terbinafine and clotrimazole creams twice a day3 mo3Excellent5(Fig. 5)57/FemaleRefractory tinea cruris from 8 months ago with severe pruritus and sleep disturbance from 14 months agotopical antifungalFluconazoleItraconazoleTerbinafineVoriconazole/ 12 monthsAblative fractional Er: Yag laser with rejuvenation mode (PSO3) with spot size 7 mm, energy 2 J, 15 Hz1Combination of topical terbinafine and clotrimazole creams twice a day1 mo3Excellent(The patient mentioned the dramatic relieve of pruritus and sleeping well) Patient Demographic, Clinical, and Treatment Information 1 (Fig. 1) topical antifungal Fluconazole Itraconazole Terbinafine Voriconazole / 12 months 2 (Fig. 2) topical antifungal Fluconazole Itraconazole Terbinafine / 10 months Combination of topical terbinafine and clotrimazole creams twice a day/ Weekly oral fluconazole 150 3 (Fig. 3) topical antifungal Fluconazole Itraconazole Terbinafine Combination of Itraconazole and terbinafine / 11 months Combination of topical terbinafine and clotrimazole creams twice a day/ Weekly oral fluconazole 150 4 (Fig. 4) topical antifungal Itraconazole Terbinafine Voriconazole / 8 months 5 (Fig. 5) topical antifungal Fluconazole Itraconazole Terbinafine Voriconazole / 12 months Treatment outcomes were assessed both by the patients and by the attending dermatologist. Standardized digital photographs were taken at baseline and after the third session. A custom five-point Likert-type scale was used to rate clinical improvement as follows: worsened (-1), no change (0), slight improvement (1), moderate improvement (2), and significant improvement (3). Tolerability and any adverse effects were also recorded. Results In this study, five patients with established, prolonged dermatophyte infections were treated using laser-assisted drug delivery (LADD). The mean age was 46.2 years (range: 39–57 years), with a male-to-female ratio of 2:3. Demographic and clinical data are presented in Table 1, and the clinical presentation of each patient before and after treatment is shown in Figs. 1, 2, 3, 4 and 5. Fig. 1Pictures of patient 1 before (A), after second treatment (B), and three months after third session (C) of LADD with fractional CO2 laser Pictures of patient 1 before (A), after second treatment (B), and three months after third session (C) of LADD with fractional CO2 laser Fig. 2Pictures of patient 2 before (A), and three months after second treatment session (B) of LADD with Er: Yag laser Pictures of patient 2 before (A), and three months after second treatment session (B) of LADD with Er: Yag laser Fig. 3Pictures of patient 3, before (A), and six month later (B) of LADD with Er: Yag laser Pictures of patient 3, before (A), and six month later (B) of LADD with Er: Yag laser Fig. 4Clinical presentation of Patient 4 before (A) and after (B) two sessions of LADD Clinical presentation of Patient 4 before (A) and after (B) two sessions of LADD Fig. 5Clinical presentation of Patient 5 before (A) and after (B) a single session of LADD with dramatic itch relieve Clinical presentation of Patient 5 before (A) and after (B) a single session of LADD with dramatic itch relieve This study comprised three patients with tinea cruris (Patients 1, 4, and 5) and two with tinea corporis (Patients 2 and 3). Culture confirmed dermatophyte infection in all cases; however, species-level molecular identification was not performed as part of routine clinical care. Prior to LADD, all patients had received topical antifungal treatments along with oral antifungal medications, including fluconazole, itraconazole, and terbinafine. In addition, three of the five patients (60%) were treated with oral voriconazole. Despite being on systemic antifungal therapy for at least eight months (range, 8–12 months), all patients experienced unsatisfactory clinical responses. Treatment information is detailed in Table 1. The type of laser used in LADD was a fractional CO₂ laser in one patient (Patient 1) and an Er: YAG laser in the remaining four (Patients 2–5). Of the five patients, two completed three LADD sessions (40%), two underwent two sessions (40%), and one patient received only a single session (20%). All patients got maximum score (3) at Likert-type scale for clinical evaluation. All patients expressed excellent satisfaction with the treatment outcomes, which was supported by clinical evaluation (Figs. 1, 2, 3, 4 and 5; Table 1). A dramatic clinical improvement was observed in all five patients, including relief of pruritus and improved sleep within two weeks—particularly in the patient who underwent only one LADD session and chose not to continue further sessions due to the substantial improvement achieved. The follow-up period ranged from one to six months. During this time, none of the patients experienced recurrence of infection. All patients tolerated the procedure well. The only reported side effects were transient erythema and post-inflammatory hyperpigmentation (PIH), which was more pronounced in the patient treated with the CO₂ laser. Discussion Laser-assisted drug delivery (LADD) is emerging as a promising therapeutic approach for various dermatologic conditions, including psoriasis, vitiligo, scars, and onychomycosis [6, 8, 9]. However, to the best of our knowledge, its effectiveness has not yet been evaluated for cutaneous dermatophyte infections. In this case series, all five patients with refractory dermatophytosis achieved excellent clinical outcomes following LADD treatment. Each patient reported high satisfaction, and no recurrence was observed during the follow-up period. Although species-level identification was not performed in our study, Trichophyton rubrum is the most common dermatophyte with global distribution, also the most common pathogen of tinea corporis and cruris [10]. This pathogen decreases the proliferation rate of epidermis leading to chronicity course of the disease. Notably, refractory and treatment-resistant dermatophytoses are increasingly attributable to Trichophyton mentagrophytes and the emerging Trichophyton indotineae, which is frequently resistant to terbinafine and azoles and has spread from the Indian subcontinent worldwide [11]. The prolonged, systemic-therapy-refractory course observed in our patients is consistent with infection by such recalcitrant species. The mechanism of LADD with ablative fractional lasers involves the creation of microscopic channels or thermal zones in the skin via controlled ablation. These microchannels disrupt the stratum corneum, facilitating enhanced penetration of high-molecular-weight topical antifungal agents into deeper skin layers [5]. In addition, the laser’s thermal effects may exert a direct fungicidal action. Even mild photothermal injury has been hypothesized to impair fungal viability, which may explain the improved outcomes when laser is combined with topical antifungal therapy compared to topical therapy alone [7]. It is shown that laser therapy alters the fungal morphology with reduction of hyphae, conidia, and reproductive structures of Trichophyton rubrum, which leads to disruption of fungal growth and reproduction capacity, infection ability and virulence [12]. In the present study, two types of ablative fractional lasers were employed: fractional CO₂ laser and fractional Er: YAG laser. Laser parameters were selected to prioritize safety while ensuring sufficient ablation to facilitate drug delivery. For the fractional CO₂ laser, we used a low energy setting (14 mJ per microbeam), a short dwell time (100 µs), a single pulse per spot (stack 1), and wide spacing (~ 400 μm between micro-spots). These conservative settings aimed to disrupt the epidermal barrier adequately for drug penetration while minimizing thermal damage to reduce side effects. The Er: YAG laser was applied in “rejuvenation” mode. The Er: YAG laser, with its higher absorption in water and higher ablation-to-coagulation ratio, produces more superficial channels with minimal thermal spread. This reduces the risk of pigmentation changes, particularly in patients with darker skin. LADD has been extensively studied in the treatment of onychomycosis, where multiple studies have demonstrated improved cure rates when combining ablative lasers with topical antifungals [7, 13, 14]. According to recent systematic review, laser therapy illustrates comparable efficacy to terbinafine and fewer adverse effects [15]. These findings support the dual action of LADD—enhancing local drug bioavailability and directly damaging fungal structures. This combined mechanism likely contributed to the successful clearance of chronic, treatment-resistant dermatophyte infections in our patients. All patients tolerated the procedures well, with minimal discomfort reported. Side effects were limited to mild procedural pain and transient erythema. However, patients treated with the CO₂ laser experienced a higher incidence of post-inflammatory hyperpigmentation (PIH). While PIH is a known risk, especially with fractional lasers, it is generally self-limiting and resolves within 3–6 months. Topical depigmenting agents can be used if needed. Furthermore, since the affected areas in our study were not sun-exposed, pigmentation changes resolved more rapidly. Importantly, no systemic adverse effects or drug interactions were observed, a notable advantage over oral antifungal treatments. Given the growing resistance to systemic antifungals and the burden of chronic dermatophytosis, ablative fractional lasers offer an accessible and effective alternative therapy. However, further studies with larger sample sizes and longer follow-up durations are needed to confirm these preliminary findings. Limitation The main limitations of this study are the small sample size and the relatively short follow-up period. As a case series, it lacks a control group and statistical power, limiting the generalizability of the results. In addition, the dermatophyte species was not identified at the molecular level, precluding correlation of treatment response with the causative organism. Finally, two different ablative fractional laser platforms were used, with only a single patient treated with the CO₂ laser, introducing heterogeneity that limits platform-specific conclusions. Conclusion The results of this case series suggest that laser-assisted drug delivery may be a promising alternative treatment for patients with longstanding, treatment-refractory tinea cruris and tinea corporis, prone to recurrence after treatment discontinuation, or when systemic therapy is contraindicated. Future larger-scale, controlled studies are warranted to validate these findings and further establish the role of LADD in the management of cutaneous dermatophyte infections.